BridgeBio Oncology Therapeutics (BBOT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.82, -4.41% vs the prior close of $2.95.
- Volume 480.76K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BBOT slides 4.4% to $2.82, a 52-week low. Closed at $2.82, -4.41% vs the prior close of $2.95. Day range $2.81–$2.95, opened at $2.95.
BBOT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BBOT slides 4.4% to $2.82, a 52-week low
- Closed at $2.82, -4.41% vs the prior close of $2.95. Day range $2.81–$2.95, opened at $2.95.
- Volume was 480.76K shares, 0.9x its 50-day average of 521.51K.
- Price is -55.2% vs its 50-day average ($6.30) and -67.3% vs its 200-day average ($8.61).
- 52-week range $2.81–$14.87; today's close sits at 0% of that range, 81.0% below the 52-week high.
Oct 15, 2026 — BBOT rises 1.5% to $2.95
- Closed at $2.95, +1.55% vs the prior close of $2.90. Day range $2.86–$3.30, opened at $2.90.
- Volume was 473.90K shares, 0.9x its 50-day average of 514.98K.
- Price is -54.0% vs its 50-day average ($6.42) and -65.9% vs its 200-day average ($8.66).
- 52-week range $2.86–$14.87; today's close sits at 1% of that range, 80.2% below the 52-week high.
Oct 14, 2026 — BBOT dips 1.5% to $2.90, a 52-week low, 10 down days in a row
- Closed at $2.90, -1.53% vs the prior close of $2.95. Day range $2.88–$3.07, opened at $2.94.
- Volume was 440.60K shares, 0.9x its 50-day average of 516.31K.
- Price is -55.6% vs its 50-day average ($6.54) and -66.6% vs its 200-day average ($8.71).
- 52-week range $2.88–$14.87; today's close sits at 0% of that range, 80.5% below the 52-week high.
- That makes 10 straight losses.
Oct 13, 2026 — BBOT slides 9.5% to $2.95, a 52-week low, 9 down days in a row
- Closed at $2.95, -9.51% vs the prior close of $3.26. Day range $2.93–$3.34, opened at $3.24.
- Volume was 505.70K shares, 1.0x its 50-day average of 510.40K.
- Price is -55.7% vs its 50-day average ($6.66) and -66.3% vs its 200-day average ($8.75).
- 52-week range $2.93–$14.87; today's close sits at 0% of that range, 80.2% below the 52-week high.
- That makes 9 straight losses.
Oct 12, 2026 — BBOT dips 1.5% to $3.26, a 52-week low, 8 down days in a row
- Closed at $3.26, -1.51% vs the prior close of $3.31. Day range $3.23–$3.37, opened at $3.31.
- Volume was 234.00K shares, 0.5x its 50-day average of 513.08K — lighter than usual.
- Price is -51.8% vs its 50-day average ($6.77) and -63.0% vs its 200-day average ($8.80).
- 52-week range $3.23–$14.87; today's close sits at 0% of that range, 78.1% below the 52-week high.
- That makes 8 straight losses.
Oct 9, 2026 — BBOT slides 3.2% to $3.31, a 52-week low, 7 down days in a row
- Closed at $3.31, -3.22% vs the prior close of $3.42. Day range $3.30–$3.50, opened at $3.43.
- Volume was 472.00K shares, 0.9x its 50-day average of 509.51K.
- Price is -51.8% vs its 50-day average ($6.86) and -62.6% vs its 200-day average ($8.84).
- 52-week range $3.27–$14.87; today's close sits at 0% of that range, 77.7% below the 52-week high.
- That makes 7 straight losses.
Oct 8, 2026 — BBOT dips 0.6% to $3.42, a 52-week low, 6 down days in a row
- Closed at $3.42, -0.58% vs the prior close of $3.44. Day range $3.27–$3.43, opened at $3.43.
- Volume was 566.20K shares, 1.1x its 50-day average of 505.92K.
- Price is -50.9% vs its 50-day average ($6.97) and -61.5% vs its 200-day average ($8.89).
- 52-week range $3.27–$14.87; today's close sits at 1% of that range, 77.0% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — BBOT dips 1.7% to $3.44, a 52-week low, 5 down days in a row
- Closed at $3.44, -1.71% vs the prior close of $3.50. Day range $3.36–$3.57, opened at $3.46.
- Volume was 321.30K shares, 0.6x its 50-day average of 502.08K.
- Price is -51.3% vs its 50-day average ($7.06) and -61.5% vs its 200-day average ($8.93).
- 52-week range $3.36–$14.87; today's close sits at 1% of that range, 76.9% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — BBOT dips 2.8% to $3.50, a 52-week low, 4 down days in a row
- Closed at $3.50, -2.78% vs the prior close of $3.60. Day range $3.48–$3.72, opened at $3.60.
- Volume was 659.70K shares, 1.3x its 50-day average of 493.71K.
- Price is -51.2% vs its 50-day average ($7.16) and -61.0% vs its 200-day average ($8.98).
- 52-week range $3.48–$14.87; today's close sits at 0% of that range, 76.5% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — BBOT slides 7.5% to $3.60, a 52-week low, 3 down days in a row
- Closed at $3.60, -7.46% vs the prior close of $3.89. Day range $3.58–$3.88, opened at $3.88.
- Volume was 481.60K shares, 1.0x its 50-day average of 487.80K.
- Price is -50.5% vs its 50-day average ($7.27) and -60.1% vs its 200-day average ($9.02).
- 52-week range $3.58–$14.87; today's close sits at 0% of that range, 75.8% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — BBOT dips 1.3% to $3.89
- Closed at $3.89, -1.27% vs the prior close of $3.94. Day range $3.88–$4.05, opened at $3.97.
- Volume was 486.00K shares, 1.0x its 50-day average of 483.23K.
- Price is -47.2% vs its 50-day average ($7.37) and -57.1% vs its 200-day average ($9.06).
- 52-week range $3.79–$14.87; today's close sits at 1% of that range, 73.8% below the 52-week high.
BBOT latest news & SEC filings
Every SEC filing by or about BBOT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cobo Marc had withheld for taxes 126 shares at $3.94 (≈$496) on Oct 1, 2026; now holds 14,015
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Elmelech Idan had withheld for taxes 343 shares at $3.94 (≈$1.35K) on Oct 1, 2026; now holds 14,152
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Beltran Pedro had withheld for taxes 1,047 shares at $3.94 (≈$4.13K) on Oct 1, 2026; now holds 43,529
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ben Yong had withheld for taxes 1,047 shares at $3.94 (≈$4.13K) on Oct 1, 2026; now holds 43,529
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 1, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 12, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$56.45M (prior year -$28.43M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$705.20 (prior year -$566.46) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 6, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade BBOT
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 5, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.43% (largest 10.7%). That is a volatile stock.
- Liquidity: about 546.66K shares (≈$1.54M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.82 vs a range of $2.81–$14.87 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 8, 2026; 10-Q Aug 11, 2026; 8-K Aug 11, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BBOT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.95 | 2.95 | 2.81 | 2.82 | 480.76K |
| Oct 15, 2026 | 2.90 | 3.30 | 2.86 | 2.95 | 473.90K |
| Oct 14, 2026 | 2.94 | 3.07 | 2.88 | 2.90 | 440.60K |
| Oct 13, 2026 | 3.24 | 3.34 | 2.93 | 2.95 | 505.70K |
| Oct 12, 2026 | 3.31 | 3.37 | 3.23 | 3.26 | 234.00K |
| Oct 9, 2026 | 3.43 | 3.50 | 3.30 | 3.31 | 472.00K |
| Oct 8, 2026 | 3.43 | 3.43 | 3.27 | 3.42 | 566.20K |
| Oct 7, 2026 | 3.46 | 3.57 | 3.36 | 3.44 | 321.30K |
| Oct 6, 2026 | 3.60 | 3.72 | 3.48 | 3.50 | 659.70K |
| Oct 5, 2026 | 3.88 | 3.88 | 3.58 | 3.60 | 481.60K |
| Oct 2, 2026 | 3.97 | 4.05 | 3.88 | 3.89 | 486.00K |
| Oct 1, 2026 | 4.05 | 4.10 | 3.82 | 3.94 | 1.36M |
| Sep 30, 2026 | 3.94 | 4.15 | 3.88 | 4.10 | 736.30K |
| Sep 29, 2026 | 3.83 | 4.02 | 3.80 | 3.92 | 537.40K |
| Sep 28, 2026 | 3.91 | 3.92 | 3.79 | 3.81 | 476.60K |
| Sep 25, 2026 | 4.00 | 4.00 | 3.89 | 3.95 | 523.50K |
| Sep 24, 2026 | 4.15 | 4.17 | 3.90 | 3.99 | 656.60K |
| Sep 23, 2026 | 4.61 | 4.70 | 4.05 | 4.16 | 539.60K |
| Sep 22, 2026 | 4.63 | 4.81 | 4.60 | 4.66 | 509.10K |
| Sep 21, 2026 | 4.84 | 4.84 | 4.59 | 4.66 | 468.70K |
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics (BBOT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1869105.
BBOT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jake Bauer | Director | Jun 18, 2026 |
| Pedro Beltran | President and CEO | Jul 6, 2026 |
| Bihua Chen | Director | Jul 6, 2026 |
| Raymond J. Kelleher | Director | Jun 18, 2026 |
| Neil Kumar | Director | Jun 18, 2026 |
| Peter F Lebowitz | Director | Jun 18, 2026 |
| Frank Mccormick | Director | Jun 18, 2026 |
| Praveen P. Tipirneni | Director | Jun 18, 2026 |
| Eli M. Wallace | Chief Executive Officer | Jan 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Pedro Beltran | President and CEO | Jul 6, 2026 |
| Yong Ben | Chief Med & Dev Officer | Jul 6, 2026 |
| Marc Cobo | Principal Accounting Officer | Sep 14, 2026 |
| Idan Elmelech | COO & Principal Financial Ofcr | Jul 6, 2026 |
| Eli M. Wallace | Chief Executive Officer | Jan 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
BBOT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-134.04M | -4.30 | $-113.89M |
| Dec 31, 2024 | — | $-74.28M | -5,756.41 | $-55.03M |
| Dec 31, 2023 | — | $-41.69K | — | — |
Latest balance sheet: total assets $376.71M, total liabilities $53.59M, cash $54.06M (as of Jun 30, 2026).
BBOT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $9.20 |
| May 12, 2026 | 8-K Item 2.02 (results) | $8.13 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $9.89 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $12.63 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BBOT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.